Drug intelligence / Profile preview

letrozole + nintedanib

Development stage: Unknown
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Oral

Overview

Letrozole + nintedanib is a combination therapy being investigated for breast cancer treatment. Letrozole is an aromatase inhibitor that reduces estrogen production, while nintedanib is a multikinase inhibitor targeting FGFR1 and other pathways. This combination aims to provide dual inhibition of hormone-dependent growth pathways and angiogenesis in hormone-receptor positive breast cancer.

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)CYP19A1 (Aromatase)

Beyond the preview

Go deeper on letrozole + nintedanib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on letrozole + nintedanib.

Explore the full profile